Last Updated: June 25, 2026

Details for Patent: 10,172,864

Name: Drug Patent Intelligence for US Patent 10172864
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,172,864 protect, and when does it expire?

Patent 10,172,864 protects VORANIGO and is included in one NDA.

This patent has seventy-four patent family members in forty countries.

Summary for Patent: 10,172,864

Title:	Therapeutically active compounds and their methods of use
Abstract:	Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Inventor(s):	Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
Assignee:	PHARMARESOURCES (SHANGHAI) CO Ltd , Servier Pharmaceuticals LLC
Application Number:	US15/392,681
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,172,864

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,172,864

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3019483	⤷ Start Trial	C03019483/01	Switzerland	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	C20265008	Finland	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	301370	Netherlands	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	CR 2026 00011	Denmark	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	PA2026510	Lithuania	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	2026C/707	Belgium	⤷ Start Trial
European Patent Office	3019483	⤷ Start Trial	122026000022	Germany	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.